Novartis to present new data across oncology portfolio including Kisqali Phase III NATALEE trial in early breast cancer at ASCO
April 26, 2023 10:21 ET
|
Novartis Pharma AG
Primary analysis of NATALEE, the first and only positive Phase III study of a CDK4/6 inhibitor in a broad population of patients with stage II and III HR+/HER2- early breast cancer at risk of...
Novartis Phase III APPOINT-PNH trial shows investigational oral monotherapy iptacopan improves hemoglobin to near-normal levels, leading to transfusion independence in all treatment-naïve PNH patients
April 26, 2023 05:30 ET
|
Novartis Pharma AG
Data at EBMT show primary endpoint met – estimated* 92.2% of complement-inhibitor-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) achieving 2 g/dL or more hemoglobin-level increase from...
Novartis erzielt kräftige Umsatzsteigerungen, eine robuste Margenerhöhung und wichtige Innovationsmeilensteine. Erhöhung der Jahresprognose
April 25, 2023 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Umsatz wuchs im ersten Quartal um +8% (kWk1, +3% USD), und das operative Kernergebnis verbesserte sich um +15% (kWk, +8% USD) Innovative Medicines (IM)...
Novartis réalise une croissance forte de son chiffre d’affaires, une expansion robuste de sa marge, des étapes majeures de l’innovation et rehausse ses prévisions pour l’exercice 2023
April 25, 2023 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RC Au T1, chiffre d’affaires en hausse de +8% (tcc1, +3% USD) et du résultat opérationnel de +15% (tcc, +8% USD) Innovative Medicines (IM): hausse de...
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
April 25, 2023 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q1 sales grew +8% (cc1, +3% USD) and core operating income grew +15% (cc, +8% USD) Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core...
Novartis presents new five-year data on disability outcomes and safety of Kesimpta® (ofatumumab) in people living with relapsing multiple sclerosis
April 20, 2023 01:15 ET
|
Novartis Pharma AG
The ALITHIOS open-label extension study showed continuous treatment with Kesimpta® (ofatumumab) for up to five years in relapsing multiple sclerosis (RMS) patients was associated with reduced risk of...
Novartis Entresto receives positive CHMP opinion for pediatric heart failure
March 31, 2023 07:53 ET
|
Novartis Pharma AG
If subsequently approved, Entresto will be the first and only approved therapy for the treatment of symptomatic chronic heart failure patients aged 1 to <18 years in the European Union Pediatric...
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
March 27, 2023 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is...
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
March 16, 2023 18:47 ET
|
Novartis Pharma AG
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months...
Aktionärinnen und Aktionäre von Novartis heissen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats gut
March 07, 2023 08:01 ET
|
Novartis Pharma AG
Die Aktionärinnen und Aktionäre genehmigen die 26. Dividendenerhöhung in Folge auf CHF 3,20 (+3,2 %) pro Aktie für 2022; dies entspricht einer Rendite von 4.0 %1 und einer Ausschüttung von rund 61 %...